PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Videos|April 19, 2023
Interview with LGM Pharma’s CEO, Prasad Raje
Author(s)LGM Pharma
Key Learning Objectives:
- LGM Pharma reports strong revenues in its first year of CDMO operations and continued growth in its API Sourcing business
- Offering API sourcing and CDMO services, plus Analytical Testing and new Drug Product R&D services, addresses the comprehensive needs of customers as LGM promotes its customer-centric strategies for growth.
- LGM Pharma elevated its API sourcing network with the 2020 acquisition of NexGen Pharma’s CDMO business – enabling the one company to provide comprehensive services.
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.